Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene therapy for the hemoglobin disorders.

Derek A Persons1, Arthur W Nienhuis

  • 1St. Jude Children's Research Hospital, 332 North Lauderdale Drive, Memphis, TN 38105, USA. derek.persons@stjude.org

Current Hematology Reports
|August 7, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High level of fetal-globin reactivation by designed transcriptional activator-like effector.

Blood advances·2020
Same author

Gene Therapy for Hemophilia.

Molecular therapy : the journal of the American Society of Gene Therapy·2017
Same author

Lentiviral Transfer of γ-Globin with Fusion Gene NUP98-HOXA10HD Expands Hematopoietic Stem Cells and Ameliorates Murine β-Thalassemia.

Molecular therapy : the journal of the American Society of Gene Therapy·2017
Same author

The identification of hematopoietic-specific regulatory elements for <i>WASp</i> gene expression.

Molecular therapy. Methods & clinical development·2016
Same author

Data in support of transcriptional regulation and function of Fas-antisense long noncoding RNA during human erythropoiesis.

Data in brief·2016
Same author

Fas-antisense long noncoding RNA is differentially expressed during maturation of human erythrocytes and confers resistance to Fas-mediated cell death.

Blood cells, molecules & diseases·2016

Gene therapy offers new hope for beta-thalassemia and sickle cell disease, the most common genetic blood disorders. Lentiviral vectors show promise for correcting these conditions, advancing future treatment possibilities.

Area of Science:

  • Hematology
  • Genetic Medicine
  • Molecular Biology

Background:

  • Beta-thalassemia and sickle cell disease are prevalent genetic blood disorders with suboptimal current treatments.
  • Significant patient morbidity and mortality persist despite existing therapies like stem cell transplantation.
  • Gene therapy presents a long-sought alternative for treating these inherited hemoglobinopathies.

Purpose of the Study:

  • To review critical developments in gene therapy for hemoglobin disorders.
  • To highlight advancements in lentiviral vector technology for gene delivery.
  • To discuss progress in stem cell modification and expansion for therapeutic applications.

Main Methods:

  • Utilizing lentiviral vectors for high-level expression of globin gene cassettes.

Related Experiment Videos

  • Therapeutic correction of murine models for beta-thalassemia and sickle cell disease.
  • Investigating methods for selecting and expanding genetically modified stem cells in vivo.

    • Main Results:

    • Successful therapeutic correction of beta-thalassemia and sickle cell disease in preclinical murine models.
    • Demonstrated high-level gene expression using lentiviral vectors.
    • Advancements in in vivo stem cell manipulation techniques.

    Conclusions:

    • Gene therapy, particularly using lentiviral vectors, shows significant potential for treating beta-thalassemia and sickle cell disease.
    • Progress in gene delivery and stem cell technology brings curative gene therapy for hemoglobin disorders closer to clinical reality.
    • Further research and development are crucial for translating these advancements into effective patient treatments.